First approvals of the CAR T cell treatments in Europe present a great opportunity to fight hematological malignancies. However, the route from bench to bedside poses several challenges, demanding for a European-wide harmonization process. During the workshop the projects EURE-CART (www.eure-cart.eu) and CARAMBA (www.caramba-cart.eu) will present their current regulatory experiences and discuss those with representatives of national regulatory authorities. It is a great opportunity to analyze the lessons learnt and to define future perspectives on how to accelerate the treatment with CAR-T cells.
CAR-T, regulatory, ATMP